Basics ADMA Biologics Inc ADMA Biologics Inc is a biopharmaceutical company. The company develops and manufactures specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases. IPO Date: October 18, 2013 Sector: Healthcare Industry: Biotech Market Cap: $4.03B Activated in VL: True Average Daily Range Avg Daily Range: $0.15 | 2.76% Avg Daily Range (30 D): $0.29 | 1.64% Avg Daily Range (90 D): $0.34 | 1.76% Institutional Daily Volume Avg Daily Volume: 1.59M Avg Daily Volume (30 D): 2.81M Avg Daily Volume (90 D): 2.75M Trade Size Avg Trade Size (Sh.): 189 Avg Trade Size (Sh.) (30 D): 86 Avg Trade Size (Sh.) (90 D): 82 Institutional Trades Total Inst.Trades: 1,801 Avg Inst. Trade: $3.38M Avg Inst. Trade (30 D): $3.1M Avg Inst. Trade (90 D): $3.91M Avg Inst. Trade Volume: .32M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $5.3M Avg Closing Trade (30 D): $7.14M Avg Closing Trade (90 D): $8.49M Avg Closing Volume: 503.91K     News Aug 7, 2025 @ 2:00 PM Plasma Derived Medicine Market to Reach USD 37.4 B... Source: Towards Healthcare Jul 30, 2025 @ 11:00 AM ADMA Biologics to Report Second Quarter 2025 Finan... Source: Adma Biologics, Inc. May 6, 2025 @ 8:11 PM 3 Mid-Cap Medical Stocks Outperforming the Market Source: Marketbeat.Com Apr 7, 2025 @ 11:00 AM ADMA Biologics Statement on Tariffs Source: N/A Mar 4, 2025 @ 6:50 PM BREAKING: Block & Leviton Investigating ADMA Biolo... Source: Block & Leviton Financials   TTM Q2 2025 Q1 2025 Basic EPS $.88 $.14 $.11 Diluted EPS $.86 $.14 $.11 Revenue $ 474.17M $ 121.98M $ 114.8M Gross Profit $ 251.32M $ 67.23M $ 61.1M Net Income / Loss $ 208.93M $ 34.22M $ 26.9M Operating Income / Loss $ 155.64M $ 42.8M $ 34.88M Cost of Revenue $ 222.86M $ 54.76M $ 53.71M Net Cash Flow $ 2.04M $ 18.66M $ -31.52M PE Ratio 19.48